169 related articles for article (PubMed ID: 10079375)
1. Differential diagnostic significance of the paucity of HLA-I antigens on metastatic breast carcinoma cells in effusions.
Magyarosy E; Martin WJ; Chu EW; Martin SE
Pathol Oncol Res; 1999; 5(1):32-5. PubMed ID: 10079375
[TBL] [Abstract][Full Text] [Related]
2. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
3. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Value of the EZH2 Immunomarker in Malignant Effusion Cytology.
Ang PP; Tan GC; Karim N; Wong YP
Acta Cytol; 2020; 64(3):248-255. PubMed ID: 31352449
[TBL] [Abstract][Full Text] [Related]
5. Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions.
Johnston WW; Szpak CA; Lottich SC; Thor A; Schlom J
Cancer Res; 1985 Apr; 45(4):1894-900. PubMed ID: 3884146
[TBL] [Abstract][Full Text] [Related]
6. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated antigens in effusions of malignant and benign origin.
Ammon A; Eiffert H; Reil S; Beyer JH; Droese M; Hiddemann W
Clin Investig; 1993 Jun; 71(6):437-44. PubMed ID: 8353402
[TBL] [Abstract][Full Text] [Related]
8. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
9. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
Hafez NH; Tahoun NS
J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
[TBL] [Abstract][Full Text] [Related]
11. Detection of a soluble antigen defined by monoclonal antibody 83D4 in serous effusions associated with breast carcinoma.
Osinaga E; Pancino G; Beuzelin M; Babino A; Rodriguez D; Robello C; Tiscornia A; Phillips E; Bourguignat A; Roseto A
Cancer; 1992 Apr; 69(7):1745-9. PubMed ID: 1551059
[TBL] [Abstract][Full Text] [Related]
12. Sensitive detection of tumour cells in effusions by combining cytology and fluorescence in situ hybridisation (FISH).
Fiegl M; Massoner A; Haun M; Sturm W; Kaufmann H; Hack R; Krugmann J; Fritzer-Szekeres M; Grünewald K; Gastl G
Br J Cancer; 2004 Aug; 91(3):558-63. PubMed ID: 15226776
[TBL] [Abstract][Full Text] [Related]
13. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.
Kleinberg L; Flørenes VA; Skrede M; Dong HP; Nielsen S; McMaster MT; Nesland JM; Shih IeM; Davidson B
Virchows Arch; 2006 Jul; 449(1):31-9. PubMed ID: 16541284
[TBL] [Abstract][Full Text] [Related]
14. Tumour associated antigens in diagnosis of serous effusions.
Mezger J; Permanetter W; Gerbes AL; Wilmanns W; Lamerz R
J Clin Pathol; 1988 Jun; 41(6):633-43. PubMed ID: 2454957
[TBL] [Abstract][Full Text] [Related]
15. Soluble receptor-binding cancer antigen expressed on SiSo cells in pleural fluid: a potential diagnostic marker for malignant pleural effusion.
Aoe K; Hiraki A; Maeda T; Murakami T; Yamazaki K; Sugi K; Takeyama H
Chest; 2004 Oct; 126(4):1195-7. PubMed ID: 15486382
[TBL] [Abstract][Full Text] [Related]
16. Cytological diagnosis and telomerase activity of cells in effusions of body cavities.
Toshima S; Arai T; Yasuda Y; Takaya T; Ito Y; Hayakawa K; Shibuya C; Yoshimi N; Shibayama M; Kashiki Y
Oncol Rep; 1999; 6(1):199-203. PubMed ID: 9864428
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers in the diagnosis of malignant serous effusions.
Cascinu S; Del Ferro E; Barbanti I; Ligi M; Fedeli A; Catalano G
Am J Clin Oncol; 1997 Jun; 20(3):247-50. PubMed ID: 9167746
[TBL] [Abstract][Full Text] [Related]
18. Different expression of FoxM1 in human benign and malignant pleural effusion.
Tang Z; Li H; Zhu H; Bai C
Med Oncol; 2015 Jan; 32(1):312. PubMed ID: 25491139
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies in the cytodiagnosis of serous effusions.
al-Nafussi A; Carder PJ
Cytopathology; 1990; 1(2):119-28. PubMed ID: 1714782
[TBL] [Abstract][Full Text] [Related]
20. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
Davidson B; Elstrand MB; McMaster MT; Berner A; Kurman RJ; Risberg B; Trope CG; Shih IeM
Gynecol Oncol; 2005 Jan; 96(1):42-7. PubMed ID: 15589578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
